A series of blood tests, procedures, and imaging tests can help diagnose acute myeloid leukemia (AML). Additionally, these tests can also determine its subtype and help identify the best treatment ...
A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population. In a real-world setting of new and ...
Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...
The classification of AML and therapeutic options are now largely driven by genetically defined subtypes. Personalization of treatment relies on timely completion and reporting of cytogenetic and ...
A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return About 20,000 adults in ...
SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...
Opinion
Retail Banker International on MSNOpinion

Validating AI-driven AML outcomes under FCA supervision

Dr Janet Bastiman discusses the future of AI for AML and offers expert guidance on how best to collaborate with the FCA and other regulators ...